Molecular imaging based personalized therapy has been a fascinating concept for individualized therapeutic strategy, which is able to attain the highest efficacy and reduce adverse effects in certain patients. Theranostics, which integrates diagnostic testing to detect molecular targets for particular therapeutic modalities, is one of the key technologies that contribute to the success of perso...

BACKGROUND Various abnormalities of haemostasis have been described in patients with hyperthyroidism. The results of different studies point to the underlying thyroid disease, especially severity of hyperthyroidism and autoimmune processes, as important factors contributing to coagulation-fibrinolytic balance. The objective of this study was to investigate the association between hyperthyroidis...

Background:Induction of radioadaptive responses in cells pretreated with a low dose radiation before exposure to a high dose is well documented by many investigations. The aim of this study is to determine the frequency of chromosomal aberration in peripheral blood lymphocytes of patients treated by radioiodine I for hyperthyroidism, with or without previous thyroid scan with Tc. Material and M...

BACKGROUND AND AIM This study aimed at determining whether there is a risk regarding the development of second primary malignancies after patient exposure to the low and medium radioiodine activity used during the treatment of differentiated thyroid cancers (DTC). METHODS Second primary malignancies that occurred after DTC were detected in 1,990 patients treated between 1970 and 2003. The mea...

BACKGROUND Few data are available on therapy-related myelodysplastic syndromes and acute myeloid leukemia developing after radioiodine treatment. DESIGN AND METHODS We retrospectively analyzed 39 patients with myeloid neoplasms following radioiodine treatment, whose data were reported to the Duesseldorf Myelodysplastic Syndromes Register (8 of 3814 patients) and five other German Myelodysplas...

BACKGROUND Follicular cell thyroid carcinoma is a quite aggressive form of thyroid cancer. About 10% of follicular thyroid carcinoma shows multiple metastases: lung and bone are the most common sites of metastasis. Renal involvement from thyroid primary cancer is very rare with incidence of 4.5%-5.9%. PURPOSE We report the first laparoscopic conservative treatment of renal metastasis from thy...

Redifferentiation therapy with BRAF/MEK inhibitors to facilitate treatment with radioiodine represents a good choice for radioiodine-refractory differentiated thyroid carcinoma, but recent initial clinical outcomes were modest. MAPK rebound caused by BRAF/MEK inhibitors-induced activation of HER2/HER3 is a resistance mechanism, and combination with HER inhibitor to prevent MAPK rebound may sens...

Undesired radiation exposure to caregivers is an important problem in radioiodine therapy in thyroid carcinoma patients, especially when patient is non-ambulatory. Special precautions are needed to keep the exposure to caregivers low when higher dose of radioiodine is necessary. Here we present a case-report of a 74-year old male patient with papillary thyroid carcinoma with local invasion and...

Antithyroid drugs (ATDs) have been shown to attenuate the effectiveness of radioiodine (radioiodine ablation, RIA) therapy in Graves' disease. We undertook a study to look at the impact of iodine uptakes on the outcome of (131)I therapy. To determine the effect of prior ATD use on the duration of time to achieve cure in patients with high vs intermediate uptake Graves' disease who received a fi...

In this issue of the Journal, Schlumberger et al.1 and Mallick et al.2 describe the administration of radioiodine (iodine-131) after total thyroidectomy in patients with low-risk thyroid cancer. Postsurgical treatment has long played an important role in the management of this increasingly common cancer.2 In the United States, the incidence nearly tripled (from 2.7 to 7.7 cases per 100,000) fro...